A Nature Communications study reported that STING agonist 8803 inhibited tumor growth in human meningioma samples and reduced tumor volume and mortality in mouse models. Researchers found the STING pathway is expressed in both meningioma tumor cells and immune cells in the tumor microenvironment.
Telix Pharmaceuticals has submitted regulatory applications for TLX101-Px, a brain cancer imaging agent, to both the European Medicines Agency and the U.S. Food and Drug Administration, seeking approval for glioma diagnosis and treatment monitoring.
Northwestern Medicine researchers identified a potent immunotherapy approach targeting the STING pathway for meningiomas, the most common primary brain tumor. The experimental drug STING agonist 8803 triggered tumor cell death and immune responses in human samples and mouse models.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06930846 |
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer) |
RECRUITING | NA |
| NCT06439420 |
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial |
COMPLETED | PHASE2 |
| NCT06104488 |
A Study of Avutometinib for People With Solid Tumor Cancers |
RECRUITING | PHASE1 |
| NCT05739500 |
MRI-based Computer Aided Diagnosis Software (V1) for Glioma |
ENROLLING_BY_INVITATION | |
| NCT05660499 |
Impact of the Development of Pediatric Palliative Care |
RECRUITING | |
| NCT05634707 |
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT) |
ACTIVE_NOT_RECRUITING | EARLY_PHASE1 |
| NCT05576103 |
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients |
RECRUITING | |
| NCT05539677 |
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research |
RECRUITING | |
| NCT05328739 |
The Effect of Home Care Planned According to Orem in Patients With Primary Brain Tumor and Their Caregivers |
COMPLETED | NA |
| NCT05106296 |
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer |
RECRUITING | PHASE1 |
